Amatuximab
- Generic Name
- Amatuximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 931402-35-6
- Unique Ingredient Identifier
- 6HP0354G04
- Background
Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 124
- Registration Number
- NCT02357147
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 6
- Registration Number
- NCT01521325
- Locations
- 🇺🇸
National Cacner Institue, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath